

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 8, 2003.

*Francene Sawyer*  
Francene Sawyer

December 8, 2003  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appln. No.** : TBA 10713859  
**Applicant** : Peter Emig  
**Filed** : November 14, 2003  
**Title** : NOVEL HETEROARYL DERIVATIVES AND THEIR USE AS  
MEDICAMENTS

**TC/A.U.** : TBA  
**Examiner** : TBA

**Docket No.** : 103832-466-DIV

Mail Stop Information Disclosure Statement  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Sir:

Enclosed for filing in the above-identified application are the following items:


1. Information Disclosure Statement;
2. PTO/3B/08A (Substitute 1449 Form) (2 copies);
3. Copies of the fifteen (15) documents listed on IDS; and
4. Return Receipt Postcard.

Dated: December 8, 2003

Respectfully submitted for Applicant,

*Jing Xia*

Jing Xia, Ph.D. (Reg. No. 53,801)  
GOODWIN PROCTER LLP  
599 Lexington Avenue  
New York, NY 10022  
212.813.8955



Divisional Appln. of Peter Emig  
Information Disclosure Statement

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 8, 2003.

*Francene Sawyer*  
Francene Sawyer

December 8, 2003  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Appl. No.** : TBA  
**Applicant** : Peter Emig  
**Filed** : November 14, 2003  
**Title** : NOVEL HETEROARYL DERIVATIVES AND THEIR USE AS  
MEDICAMENTS

**TC/A.U.** : TBA  
**Examiner** : TBA

**Docket No.** : 103832-466-DIV

Mail Stop IDS  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO/SB/08 (substitute for form 1449/PTO). Copies of the listed documents are enclosed.


Applicant respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form and returning a copy to applicant.

Divisional Appln. of Peter Emig  
Information Disclosure Statement

This Information Disclosure Statement is being filed before the mailing of a first office action on the merits under 37 C.F.R. §1.97(b), and therefore no fee is necessary. However, the Commissioner is still authorized to charge any required fees to Goodwin Procter LLP Deposit Account 06-0923.


Dated: December 8, 2003

Respectfully submitted for Applicant,



---

Jing Xia, Ph.D. (Reg. No. 53,801)  
GOODWIN PROCTER LLP  
599 Lexington Avenue  
New York, NY 10022  
212.813.8955




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*(Use as many sheets as necessary)*

Application Number	TBA
Filing Date	November 14, 2003
First Named Inventor	Peter Emig et al.
Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	103832-466-DIV

## LIBNY/4266315.2





PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Use form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

<b>Sheet</b> 3 <b>of</b> 3	<b>Application Number</b>	TBA
	<b>Filing Date</b>	November 14, 2003
	<b>First Named Inventor</b>	Peter Emig et al.
	<b>Art Unit</b>	TBA
	<b>Examiner Name</b>	TBA
<b>Attorney Docket Number</b>		103832-466-DIV

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		TODD R. ELWORTHY, ANTHONY P.D.W. FORD, GARY W. BANTLE, et al., N-Arylpiperazinyl-N'-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective $\alpha 1$ -Adrenoceptor Antagonists, J. Med. Chem. 1997, 40, 2674-2687	
		ARTHUR G. TAVERAS, JEFF DESKUS, JIANPING CHAO, CYNTHIA J. CACCARO, et al., Identification of Pharmacokinetically Stable 3,10-Dibromo-8-chlorobenzocycloheptapyridine Farnesyl Protein Transferase Inhibitors with Potent Enzyme and Cellular Activities, J. Med Chem. 1999, 42, 2651-2661	
		EL-SEBAI A. IBRAHIM, I. CHAABAN and S. M. EL-KHAWASS, Synthesis of Some Quinoline Derivatives of Potential Antiamebic Activity, Pharmazie 32, H. 3 (1977), 155-156	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.